1. In Vivo
  2. >>Market Access

Podcast: Identifying The 80% Of Undiagnosed And Misdiagnosed Patients

 
• By David Wild

Vibhor Gupta, director and founder of Pangaea Data, talks to In Vivo about the value of identifying the 80% of patients with undiagnosed or misdiagnosed conditions, and how his company is addressing this need.

In Vivo Podcast
• Source: Shutterstock

Pangaea Data uses unsupervised AI to comb through over 500 million patient records from a network of data partners to find undiagnosed ones, in a privacy compliant manner.

In this episode, Vibhor Gupta, director and founder of Pangaea Data, talks to In Vivo about his company's platform, successes to date, collaborations and the importance of marrying AI with physician expertise. 

Timestamps: 

10 seconds - Introduction

1:05 - Vibhor's story and the history of Pangaea

2:45 - Pangaea's platform, finding undiagnosed patients and case studies

7:00 - What data are shared and how privacy is maintained

10:25 - Collaboration with Microsoft and other cloud providers and connecting to pharma and health care companies

12:05 - Impacts of AI developments on the Pangaea platform and "activating patients" with large language models

13:55 - Harmonizing AI with human expertise 

16:40 - The role of pharma in getting the word out about Pangaea's diagnostic platform 

More from Market Access

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By David Wild

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

 
• By Ashley Yeo

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

More from In Vivo

Deals In Depth: June 2025

 
• By Deanna Kamienski and Maureen Riordan

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.